Endogenous opioid peptides

β-endorphin (from pro-opiomelanocortin, POMC); Met-enkephalin and Leu-enkephalin (from proenkephalin); dynorphin A, dynorphin B, α-neoendorphin (from prodynorphin); nociceptin/orphanin FQ (from prepronociceptin, the fourth family); endomorphin-1 and -2 (precursor unknown). Research compounds acting on the system: enkephalinase inhibitors (RB101, PL37, opiorphin), kappa antagonists (aticaprant / JNJ-67953964 / CERC-501 / LY2456302, navacaprant / NMRA-140, BTRX-335140), naloxone and naltrexone (antagonists), low-dose naltrexone (LDN)

Cognitive & neuro

Awaiting medical reviewEN ES DE FR PT ZH+ Follow for updates

Note on this profile. This is a physiology and pharmacology reference page. The body's own opioid peptides are not medicines and are not used exogenously by anyone; the drugs that act on their receptors (morphine, buprenorphine, naloxone and others) are covered in standard pharmacology references rather than here. Community use: essentially none documented.

Summary

Class: Three families of naturally occurring neuropeptides, each cut from a larger precursor protein: β-endorphin (31 amino acids, from POMC — the same precursor as ACTH and α-MSH); the enkephalins (5 amino acids, Tyr-Gly-Gly-Phe-Met or -Leu); the dynorphins (8–17 amino acids, from prodynorphin). All share the N-terminal "opioid motif" Tyr-Gly-Gly-Phe
Mechanism: The body's own morphine-like messengers: released by neurons and the pituitary to dampen pain signals, blunt the stress response, shape reward and mood, and regulate gut, breathing and hormone release — acting on the same receptors that opioid drugs hijack
Routes studied: Intravenous and intrathecal (spinal) infusion in a small number of human studies in the late 1970s and 1980s; otherwise measured, not given. Modern research uses small-molecule or antibody tools that raise, mimic or block them
Half-life: Enkephalins: seconds (destroyed by neprilysin and aminopeptidase N — together "enkephalinase"); β-endorphin: ~20–40 minutes in plasma; dynorphins: minutes
Storage: Research reagents only
Regulatory status: Not medicines. Drugs acting on their receptors are tightly regulated; the peptides themselves are not scheduled

Doses are as reported in studies or by the community — never recommendations.

1What it is

Opium has been used for pain for millennia, but it was only in 1973 that three laboratories (Pert and Snyder; Simon; Terenius) proved the brain has specific receptors for morphine — which raised the obvious question of why. In 1975 Hughes and Kosterlitz in Aberdeen isolated the answer from pig brain: two five-amino-acid peptides, Met- and Leu-enkephalin ("in the head"), that acted exactly like morphine. β-endorphin ("endogenous morphine") was identified the following year by Li and by Guillemin as a fragment of a pituitary protein, and the dynorphins ("powerful" — dynorphin A is extraordinarily potent) by Goldstein in 1979.

The three families come from three separate genes. Pro-opiomelanocortin, made in the pituitary and hypothalamus, is cut into ACTH, melanocyte-stimulating hormones and β-endorphin — so stress, which releases ACTH, releases β-endorphin with it, into both brain and blood. Proenkephalin is expressed throughout the brain, spinal cord, adrenal medulla and gut. Prodynorphin is concentrated in the hypothalamus, hippocampus, striatum and spinal cord. Each family has a preferred receptor, and together they form a distributed system that modulates almost every function opioid drugs affect: pain, breathing, mood, reward, stress hormones, gut motility, appetite, immune cells and temperature.

These peptides are the reason opioid drugs work and the reason they are addictive: morphine, fentanyl and heroin are foreign keys that fit locks built for enkephalins and endorphins. They are also the source of the popular "endorphin rush" idea. They are not medicines. β-endorphin was infused into a handful of patients in the late 1970s and found to be analgesic but impractical — a large peptide that does not cross the blood–brain barrier well and lasts minutes. Everything since has aimed at the receptors or the degrading enzymes rather than the peptides themselves. Community/self-directed use: essentially none documented, and there is no product to use.

2How it's thought to work

Three classical receptors, all inhibitory G-protein-coupled (Gi/o). activation closes calcium channels on nerve terminals (less neurotransmitter release), opens potassium channels (hyperpolarisation), and reduces cAMP. The net effect is to quiet the neuron.

Mu (MOR, OPRM1). — preferred by β-endorphin and the endomorphins; mediates the strongest analgesia, euphoria, respiratory depression, constipation and physical dependence. Morphine's main target.

Delta (DOR, OPRD1). — preferred by enkephalins; analgesia (especially for inflammatory and chronic pain), mood elevation and anxiolysis in animal models, less respiratory depression. Delta have been pursued as safer analgesics and antidepressants.

Kappa (KOR, OPRK1). — preferred by dynorphins; analgesia at the spinal level, but also dysphoria, aversion, sedation and stress-induced relapse to drug seeking. The dynorphin–kappa system is the brain's "anti-reward" counterweight, activated by stress and chronic drug exposure.

Nociceptin receptor (NOP). — the fourth member, with its own peptide; modulates pain in both directions and is involved in anxiety and reward.

Pain gating. enkephalin-containing interneurons in the spinal dorsal horn and periaqueductal grey inhibit the transmission of pain signals; this descending inhibitory system is engaged by stress, expectation and placebo — placebo analgesia is reversed by naloxone (Levine 1978, Lancet).

Stress response. β-endorphin is co-released with ACTH; opioid peptides inhibit CRH and noradrenergic arousal, and endogenous opioid tone is thought to help terminate the stress response. Dynorphin does the opposite, mediating the dysphoric component of stress.

Reward. mu and delta activation in the ventral tegmental area and nucleus accumbens increases dopamine release and underlies the pleasure of food, social contact and sex as well as opioid drugs; kappa activation decreases dopamine and produces aversion.

Exercise. β-endorphin rises in blood during prolonged or intense exercise, but blood levels do not reflect brain levels. PET studies with opioid-receptor ligands show central opioid release during running (Boecker 2008, Cereb Cortex), while much of the "runner's high" appears to be endocannabinoid-mediated — in mice, blocking cannabinoid rather than opioid receptors abolishes running-induced anxiolysis and analgesia (Fuss 2015, PNAS), and a human study found the euphoria persisted after naltrexone (Siebers 2021, Psychoneuroendocrinology).

Other systems. gut motility (the enteric nervous system is rich in enkephalins — hence opioid constipation), immune cells (express opioid receptors and make β-endorphin at inflamed sites, giving peripheral analgesia), appetite (mu agonism increases palatable food intake), and reproduction (opioid peptides suppress GnRH, contributing to exercise- and stress-induced amenorrhoea).

The body's own opioids — endorphins, enkephalins and dynorphins — at the mu, delta and kappa receptors. All three lower calcium entry and increase potassium exit, so the neuron fires less; which receptor a ligand prefers decides whether the result is analgesia, mood change or dysphoria.Schematic — not to scale

3What the research shows

Graded B (historical)

Direct administration of the peptides in humans

Intravenous β-endorphin in small numbers of patients produced analgesia, sedation and transient mood change (Catlin 1977; Foley 1979, PNAS). Intrathecal β-endorphin gave hours-long pain relief in cancer patients (Oyama 1980, Lancet; n≈14). Trials of β-endorphin in schizophrenia and depression in the late 1970s gave inconsistent results and were not pursued (Gerner 1980, Arch Gen Psychiatry). Synthetic enkephalin analogues (e.g. FK 33-824, metkephamid) were tested as analgesics in the early 1980s with modest effect and side effects; none reached approval. These studies are of historical and mechanistic interest only. [5]

Graded A (mechanistic)

Endogenous opioids in pain modulation

Naloxone reverses placebo analgesia (Levine 1978, Lancet; replicated with imaging, Eippert 2009, Neuron), reduces the analgesia of acupuncture and transcutaneous stimulation in some studies, and increases pain in some chronic-pain states, demonstrating tonic endogenous opioid activity. PET studies show opioid-receptor occupancy changes during sustained pain and placebo (Zubieta 2001 and 2005, Science / J Neurosci). Genetic variation in OPRM1 (A118G) modestly affects pain sensitivity and opioid requirement. [4][6]

Graded B/C

Enkephalinase inhibitors

Preventing enkephalin breakdown is an alternative to giving opioids: in rodents, dual neprilysin/aminopeptidase-N inhibitors (RB101, PL37) produce analgesia without respiratory depression or tolerance (Roques 2012, Nat Rev Drug Discov). A human saliva peptide, opiorphin, does the same in rats. Racecadotril, an oral enkephalinase inhibitor, is approved in many countries for acute diarrhoea — the one clinical product built on protecting enkephalins. PL37 completed early human trials for neuropathic pain; no analgesic enkephalinase inhibitor has reached Phase 3 †. [10]

Graded A (mixed/negative)

Kappa-opioid antagonists for depression and anhedonia

Because dynorphin–kappa signalling drives stress-induced dysphoria, selective kappa antagonists were developed as antidepressants. Aticaprant (JNJ-67953964) improved anhedonia measures in the NIMH FAST-MAS Phase 2a (Krystal 2020, Nat Med) and a Phase 2 adjunctive MDD trial (2022), and entered the Phase 3 VENTURA programme; in 2025 Johnson & Johnson discontinued VENTURA after an interim analysis found insufficient efficacy †. Navacaprant (Neumora) failed its first Phase 3 (KOASTAL-1) in 2025 †. The kappa-antagonist hypothesis remains biologically compelling but clinically unproven. Buprenorphine/samidorphan (a mu-partial /antagonist combination for depression) also failed to gain approval in 2019. [11]

Graded B/C

Delta-opioid agonists and biased mu agonists

Delta agonists (e.g. AZD2327) showed antidepressant-like effects in animals but failed in a small human trial for anxious depression (Richards 2016, Psychopharmacology). "G-protein-biased" mu agonists designed to separate analgesia from respiratory depression led to oliceridine (Olinvyk, approved 2020), with modest advantage. Peripherally restricted and bivalent ligands remain research tools.

Exercise, stress and the "runner's high"

Plasma β-endorphin rises with exercise above ~60–70% VO2max (Goldfarb & Jamurtas 1997 review, Sports Med), but plasma levels are mostly pituitary output and do not cross into the brain. PET shows central opioid release after two hours of running correlated with euphoria (Boecker 2008); naltrexone did not block exercise-induced euphoria in a 2021 randomised crossover study, while mouse data point to endocannabinoids. The honest summary is that exercise engages endogenous opioids but they are probably not the main cause of the mood lift. [7]

Low-dose naltrexone (LDN)

Low-dose naltrexone is hypothesised to work by transiently blocking receptors and triggering a rebound increase in endogenous opioid peptides and receptor density. Small in fibromyalgia (Younger 2013, Arthritis Rheumatol; n=31) and Crohn's disease showed benefit; a larger Danish fibromyalgia RCT (Bruun 2024, Lancet Rheumatol; n=99) was negative. Covered more fully in its own entry if present; mentioned here as the main community-level practice that claims to act on this system. [13]

4Reported side effects and interactions

Literature-reported

Literature (peptide administration, historical). sedation, nausea, flushing, itch, mild respiratory depression and transient mood change with intravenous β-endorphin; prolonged analgesia with intrathecal use and in one report prolonged sedation. Enkephalin analogues caused nausea, dizziness and, at higher doses, the familiar opioid profile.

Literature (research drugs acting on the system). kappa antagonists were generally well tolerated (headache, pruritus, GI symptoms); enkephalinase inhibitors in early trials caused no respiratory depression; naltrexone — nausea, headache, insomnia, vivid dreams (reported with LDN), hepatotoxicity warnings at high doses.

Community-reported

none for the peptides themselves. LDN users report sleep disturbance and vivid dreams in the first weeks; this belongs to the LDN discussion rather than to endorphins.

Theoretical. any agent that raises endogenous opioid tone could in principle cause dependence or interact with prescribed opioids; enkephalinase inhibitors have so far not shown this in humans, but exposure is limited. Kappa antagonism in people with a history of substance use is theoretically protective, not harmful, but long-term data are absent.

Interactions. naloxone and naltrexone block all three peptide families' actions; opioid analgesics compete at the same receptors; ACE inhibitors and neprilysin inhibitors (sacubitril) modestly raise enkephalin levels by slowing breakdown, of unknown clinical significance; alcohol releases β-endorphin, which is part of the rationale for naltrexone in alcohol-use disorder.

Markers researchers commonly monitor

Nothing is administered clinically, so these are research measures and the markers relevant to drugs acting on the system:

Marker	Why it's watched
Plasma β-endorphin	rises with exercise, stress, acupuncture and alcohol; reflects pituitary output, not brain activity, and is of limited interpretive value. Often co-measured with ACTH and cortisol because they are released together.
CSF β-endorphin, Met-enkephalin, dynorphin	research only; altered in chronic pain, depression and after spinal cord injury in small studies.
PET opioid-receptor binding ([11C]carfentanil, [11C]diprenorphine)	the gold-standard in-vivo measure of endogenous opioid release and receptor availability.
Quantitative sensory testing and conditioned pain modulation	behavioural measures of descending (partly opioid) pain inhibition.
Cortisol and ACTH	stress-axis markers when studying opioid modulation of stress; opioid antagonists raise cortisol acutely.
LH / testosterone / oestradiol	opioid tone suppresses GnRH; chronic opioid users show hypogonadism, and naltrexone raises LH.
Respiratory rate and oxygen saturation, bowel habit	the clinical safety markers for any mu-receptor activity.
Liver enzymes	with naltrexone at standard doses.

Free for everyone. Safety information is never behind a paywall.

5Reconstitution and handling

β-endorphin, enkephalins and dynorphins exist only as research-grade peptides for laboratory use, stored frozen and dissolved immediately before use (enkephalins degrade within minutes in biological fluids). They have no pharmaceutical presentation and no self-administered dose; the historical intravenous and intrathecal studies were hospital experiments under anaesthetic supervision. The site calculator is not applicable.

6Commonly studied alongside

Oxytocin and vasopressin (fellow neuropeptides in social and stress research), substance P and CGRP (pain-transmitting peptides the opioid system opposes), CRH and ACTH (the stress axis β-endorphin is released with), α-MSH and the melanocortins (the other POMC products — relevant to how setmelanotide and bremelanotide act), kisspeptin and GnRH (reproductive suppression by opioids), low-dose naltrexone, Selank and Semax (Russian peptides claimed to modulate enkephalin breakdown — see those profiles), the endocannabinoids (the other half of the exercise-euphoria story).

Informational cross-links. Not stack recommendations.

7Regulatory status by region

Region	Status (checked —)
United States	The peptides are not medicines and not controlled substances. Drugs acting on their receptors are mostly Schedule II–IV controlled substances or prescription-only (naloxone is over-the-counter since 2023). No kappa antagonist or enkephalinase inhibitor is approved for a CNS indication; racecadotril is not approved in the US
European Union	As above; racecadotril (an enkephalinase inhibitor) is approved in many member states for acute diarrhoea
United Kingdom	As EU; racecadotril licensed
Australia	Opioid-receptor drugs scheduled under the Poisons Standard; racecadotril registered †
South Africa	Opioid-receptor drugs scheduled; peptides not regulated as medicines
Sport	β-endorphin, enkephalins and dynorphins are not listed by WADA. Opioid narcotics (morphine, fentanyl, oxycodone and others) are prohibited in competition (S7). Tramadol was added to the in-competition list in 2024

8Open questions

Why have kappa antagonists repeatedly failed in late-stage depression trials despite strong preclinical and early-phase data — patient selection, dose, or a wrong hypothesis?
Can enkephalinase inhibitors deliver opioid-level analgesia without tolerance and dependence in humans?
What exactly is the endogenous opioid contribution to exercise-induced mood change, versus endocannabinoids and other mediators?
Does low-dose naltrexone actually raise endogenous opioid tone in people, and does that explain its mixed trial record?
How do individual differences in endogenous opioid function shape vulnerability to opioid addiction and chronic pain?

9References

1Hughes J et al. (1975). Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. PubMed · DOI
2Pert CB, Snyder SH (1973). Opiate receptor: demonstration in nervous tissue. Science. PubMed · DOI
3Goldstein A et al. (1979). Dynorphin-(1-13), an extraordinarily potent opioid peptide. Proc Natl Acad Sci USA. PubMed · DOI
4Levine JD, Gordon NC, Fields HL (1978). The mechanism of placebo analgesia. Lancet. PubMed · DOI
5Foley KM et al. (1979). β-Endorphin: analgesic and hormonal effects in humans. Proc Natl Acad Sci USA. PubMed · DOI
6Zubieta JK et al. (2001). Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science. PubMed · DOI
7Boecker H et al. (2008). The runner's high: opioidergic mechanisms in the human brain. Cereb Cortex. PubMed · DOI
8Fuss J et al. (2015). A runner's high depends on cannabinoid receptors in mice. Proc Natl Acad Sci USA. PubMed · DOI
9Siebers M et al. (2021). Exercise-induced euphoria and anxiolysis do not depend on endogenous opioids in humans. Psychoneuroendocrinology. PubMed · DOI
10Roques BP, Fournié-Zaluski MC, Wurm M (2012). Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain. Nat Rev Drug Discov. PubMed · DOI
11Krystal AD et al. (2020). A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. PubMed · DOI
12Johnson & Johnson (2025). Statement on the VENTURA development programme for aticaprant (company release) [verify]. PubMed
13Bruun KD et al. (2024). Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. Lancet Rheumatol. PubMed
14Bruchas MR, Land BB, Chavkin C (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. PubMed · DOI
15Corder G et al. (2018). Endogenous and exogenous opioids in pain. Annu Rev Neurosci. PubMed · DOI

References are being resolved to PubMed/DOI identifiers; links search PubMed for the citation until then.

† Being confirmed by our reviewers against current sources.

10Community

forum threads →

community protocols include this →

Threads and protocols are visible to members. Joining is free.

Self-reported side effects Phase 2

Not enough data yet. 0 of the 50 members needed have logged this compound for 4+ weeks. We don't show anything below 50, so no one can be identified.

11Page history

30 Oct 2026Profile published — awaiting medical review

Licensed CC BY-NC-SA 4.0. Found an error? Report it · Editorial standards — corrections are logged here.